Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Deckers Brands has raised its full-year revenue growth outlook by 15% after delivering record quarterly revenue in Q3 of 2025 ...

BofA analyst Jason Gerberry lowered the firm’s price target on Teva (TEVA) to $23 from $26 and keeps a Buy rating on the shares. For FY25, the ...

Deckers Brands (DECK) stock dropped Friday afternoon despite a third quarter revenue beat, as Wall Street was disappointed by ...

Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

So, Teva is very proud to be bringing forward an ... As we have communicated previously, sale of these legacy brands and generics product rights is in-line with our strategy to constantly optimize ...

Shares of Deckers Outdoor were down nearly 20% Friday afternoon, one day after the footwear maker released its quarterly results.